Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Urogenital Neoplasms 1Thymoma 1Stomach Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Liver Neoplasms 1Genital Neoplasms, Female 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Advanced Primary Liver Cancer 1Adrenocortical Carcinoma 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 2pembrolizumab 1lenvatinib 1fluzoparib 1apatinib 1Surgical Procedures, Operative 1Quality of Life 1Paclitaxel 1Nutritional Status 1Neoadjuvant Therapy 1Interviews as Topic 1Indocyanine Green 1Drug Therapy 1Diagnostic Imaging 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Carcinoma, Ovarian Epithelial × lenvatinib × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡